1. Mryashita T and Reed JC. Bcl-2 gene transfer increases relative resistance of s49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 1992;52:5407–5411.
2. Fisher TC, Milner AE, Gregory CD, et al. Bcl -2 modulation of apoptosis induced by anticancer drugs: resistance to thynidylate stress is independent of classical resistance pathways. Cancer Res. 1993;53:3321–3326.
3. van de Donk NW, Kamphuis MM, van Dijk M, et al. Chemosensitization of myeloma plasma cells by an antisense -mediated downregulation of Bcl -2 protein. Leukemia. 2003; 17:211–219.
4. Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 2003;10l: 425–432.
5. Klasa RJ, Bally MB, Ng R, et al.Eradication of human non -Hodgkin’s lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low -dose cyclophosphamide. Clin Cancer Res. 2000;6:2492–2500.